<!DOCTYPE html><html lang="en"> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>Module 4: Neurological & Psychiatric Emergencies</title> <style> /* Main Styles from Previous Document - EXACT MATCH */ body { font-family: 'Calibri', 'Segoe UI', sans-serif; line-height: 1.5; color: #2c3e50; margin: 2cm; background-color: #ffffff; counter-reset: chapter section figure table; }
    h1 {
        font-size: 28pt;
        font-weight: bold;
        color: #1a5276;
        text-align: center;
        border-bottom: 3px double #3498db;
        padding-bottom: 10px;
        margin-bottom: 30px;
    }
    
    h2 {
        font-size: 18pt;
        font-weight: bold;
        color: #ffffff;
        background-color: #2980b9;
        padding: 10px 15px;
        border-radius: 5px;
        margin-top: 30px;
        page-break-after: avoid;
    }
    
    h3 {
        font-size: 14pt;
        font-weight: bold;
        color: #154360;
        margin-top: 20px;
        margin-bottom: 10px;
        page-break-after: avoid;
    }
    
    h4 {
        font-size: 12.5pt;
        font-weight: bold;
        color: #21618c;
        margin-top: 15px;
        margin-bottom: 8px;
    }
    
    .module-title {
        font-size: 20pt;
        font-weight: bold;
        color: #21618c;
        margin-top: 40px;
        border-left: 6px solid #3498db;
        padding-left: 15px;
    }
    
    .chapter-number {
        background-color: #3498db;
        color: white;
        padding: 5px 12px;
        border-radius: 50%;
        display: inline-block;
        margin-right: 10px;
        font-weight: bold;
    }
    
    /* Lists */
    ul, ol {
        padding-left: 1.5em;
        margin-bottom: 1em;
    }
    
    li {
        margin-bottom: 8px;
        font-size: 11.5pt;
    }
    
    .sub-list {
        list-style-type: lower-alpha;
        padding-left: 2.5em;
    }
    
    .drug-list {
        columns: 2;
        column-gap: 50px;
        margin-top: 15px;
    }
    
    .drug-list li {
        break-inside: avoid;
    }
    
    /* Special Boxes - EXACT MATCH */
    .study-format {
        background-color: #e8f4fc;
        border: 1px solid #aed6f1;
        border-left: 6px solid #2e86c1;
        padding: 20px;
        margin-top: 30px;
        page-break-inside: avoid;
    }
    
    .clinical-pearl {
        background-color: #fff3cd;
        border: 1px solid #ffeaa7;
        border-left: 6px solid #fdcb6e;
        padding: 15px;
        margin: 15px 0;
        border-radius: 0 5px 5px 0;
    }
    
    .warning-box {
        background-color: #f8d7da;
        border: 1px solid #f5c6cb;
        border-left: 6px solid #e74c3c;
        padding: 15px;
        margin: 15px 0;
        border-radius: 0 5px 5px 0;
    }
    
    .definition-box {
        background-color: #d1ecf1;
        border: 1px solid #bee5eb;
        border-left: 6px solid #17a2b8;
        padding: 15px;
        margin: 15px 0;
        border-radius: 0 5px 5px 0;
    }
    
    /* Tables - EXACT MATCH */
    .comparison-table {
        width: 100%;
        border-collapse: collapse;
        margin: 20px 0;
        font-size: 11pt;
    }
    
    .comparison-table th {
        background-color: #2980b9;
        color: white;
        padding: 10px;
        text-align: left;
        border: 1px solid #1a5276;
    }
    
    .comparison-table td {
        padding: 10px;
        border: 1px solid #ddd;
        vertical-align: top;
    }
    
    .comparison-table tr:nth-child(even) {
        background-color: #f8f9fa;
    }
    
    /* Figures and Captions - EXACT MATCH */
    .figure {
        text-align: center;
        margin: 20px 0;
        page-break-inside: avoid;
    }
    
    .figure img {
        max-width: 100%;
        height: auto;
    }
    
    .caption {
        font-style: italic;
        font-size: 10.5pt;
        color: #666;
        margin-top: 5px;
        text-align: center;
    }
    
    /* Page Layout - EXACT MATCH */
    .page-break {
        page-break-before: always;
    }
    
    .footer-note {
        font-size: 9pt;
        color: #7f8c8d;
        text-align: center;
        margin-top: 30px;
        border-top: 1px solid #ecf0f1;
        padding-top: 10px;
    }
    
    /* Drug Template - EXACT MATCH */
    .drug-template {
        background-color: #f9f9f9;
        border: 1px solid #ddd;
        padding: 20px;
        margin: 25px 0;
        border-radius: 5px;
        page-break-inside: avoid;
    }
    
    .drug-template h4 {
        color: #2c3e50;
        border-bottom: 2px solid #3498db;
        padding-bottom: 5px;
        margin-top: 0;
    }
    
    .template-section {
        margin-bottom: 15px;
    }
    
    .template-label {
        font-weight: bold;
        color: #2980b9;
        display: inline-block;
        width: 180px;
    }
    
    /* Emoji Styling - EXACT MATCH */
    .emoji {
        font-size: 1.2em;
    }
    
    /* Print Specific - EXACT MATCH */
    @media print {
        body {
            margin: 1.5cm;
            font-size: 11pt;
        }
        
        .page-break {
            page-break-before: always;
        }
        
        .no-print {
            display: none;
        }
        
        a {
            color: black;
            text-decoration: none;
        }
    }
    
    /* Learning Objectives - EXACT MATCH */
    .learning-objectives {
        background-color: #e8f6f3;
        border: 1px solid #a2d9ce;
        padding: 15px;
        margin: 20px 0;
        border-radius: 5px;
    }
    
    .objective-list {
        list-style-type: none;
        padding-left: 0;
    }
    
    .objective-list li:before {
        content: "‚úì ";
        color: #27ae60;
        font-weight: bold;
        margin-right: 10px;
    }
    
    /* Additional Styles for Module 4 */
    .neuro-box {
        background-color: #e8f4fc;
        border: 2px solid #5dade2;
        padding: 20px;
        margin: 20px 0;
        border-radius: 8px;
    }
    
    .seizure-alert {
        background-color: #fdebd0;
        border: 2px solid #f39c12;
        color: #d35400;
        padding: 15px;
        margin: 20px 0;
        font-weight: bold;
        border-radius: 5px;
        text-align: center;
    }
    
    .status-epilepticus-box {
        background-color: #f2d7d5;
        border: 2px solid #c0392b;
        padding: 20px;
        margin: 20px 0;
        border-radius: 8px;
        font-weight: bold;
    }
    
    .psych-box {
        background-color: #f4ecf7;
        border: 2px solid #8e44ad;
        padding: 20px;
        margin: 20px 0;
        border-radius: 8px;
    }
    
    .overdose-alert {
        background-color: #fef9e7;
        border: 2px solid #f1c40f;
        padding: 15px;
        margin: 15px 0;
        border-radius: 5px;
    }
    
    .icp-alert {
        background-color: #d5f4e6;
        border: 2px solid #45b39d;
        padding: 15px;
        margin: 15px 0;
        border-radius: 5px;
    }
    
    /* Module 4 Specific Colors */
    .neuro-purple {
        color: #8e44ad;
        font-weight: bold;
    }
    
    .seizure-orange {
        color: #e67e22;
        font-weight: bold;
    }
    
    .psych-red {
        color: #c0392b;
        font-weight: bold;
    }
    
    .sedation-blue {
        color: #2980b9;
        font-weight: bold;
    }
</style>
</head> <body>
<div class="module-title">
    <span class="emoji">üü¶</span> MODULE 4: NEUROLOGICAL & PSYCHIATRIC EMERGENCIES
    <div style="font-size: 12pt; font-weight: normal; font-style: italic; color: #7f8c8d;">
        (Status Epilepticus, Raised ICP, Drug Overdose, Acute Agitation)
    </div>
</div>

<div class="learning-objectives">
    <h3 style="color: #148f77; margin-top: 0;">üìñ Learning Objectives</h3>
    <ul class="objective-list">
        <li>Master the management of status epilepticus (phases and drug choices)</li>
        <li>Understand management of raised intracranial pressure (ICP)</li>
        <li>Learn appropriate sedation for acute agitation and delirium</li>
        <li>Recognize and manage opioid overdose and withdrawal</li>
        <li>Differentiate between benzodiazepines (diazepam, midazolam, lorazepam)</li>
        <li>Understand antiepileptic drugs for emergency use (phenytoin, fosphenytoin, phenobarbital)</li>
        <li>Manage alcohol and benzodiazepine withdrawal</li>
        <li>Apply knowledge to clinical scenarios and exam questions</li>
    </ul>
</div>

<!-- INTRODUCTION -->
<h2><span class="chapter-number">0</span> Introduction: Brain Under Threat</h2>

<div class="warning-box">
    <strong>‚ö†Ô∏è BRAIN CELLS DIE QUICKLY:</strong> For every minute of status epilepticus, irreversible neuronal damage occurs. For every 1 mmHg rise in ICP above 20, cerebral perfusion decreases. Time is brain tissue.
</div>

<div class="clinical-pearl">
    <strong>üß† Core Concept:</strong> Neurological emergencies involve four key threats:<br>
    1. <strong class="neuro-purple">Electrical storm</strong> (seizures, status epilepticus)<br>
    2. <strong class="neuro-purple">Pressure crisis</strong> (raised ICP, herniation)<br>
    3. <strong class="neuro-purple">Chemical assault</strong> (overdose, withdrawal)<br>
    4. <strong class="neuro-purple">Behavioral emergency</strong> (agitation, psychosis)<br>
    Each requires specific pharmacological approaches.
</div>

<!-- CHAPTER 1: STATUS EPILEPTICUS MANAGEMENT -->
<h2><span class="chapter-number">1</span> Status Epilepticus: Definition & Phases</h2>

<div class="definition-box">
    <strong>Status Epilepticus:</strong> A condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms that lead to abnormally prolonged seizures. Defined as:
    ‚Ä¢ ‚â•5 minutes of continuous seizure activity OR
    ‚Ä¢ ‚â•2 seizures without full recovery of consciousness between them
</div>

<h3>1.1 Phases of Status Epilepticus</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 15%;">Phase</th>
            <th>Time Frame</th>
            <th>Pathophysiology</th>
            <th>Treatment Goals</th>
            <th>Drug Choices</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong class="seizure-orange">Early</strong></td>
            <td>0-30 minutes</td>
            <td>Excessive neuronal firing, GABA receptors still functional</td>
            <td>Stop seizure, protect airway</td>
            <td>Benzodiazepines (first-line)</td>
        </tr>
        <tr>
            <td><strong class="seizure-orange">Established</strong></td>
            <td>30-60 minutes</td>
            <td>GABA receptor internalization, glutamate excitotoxicity</td>
            <td>Stop seizure, prevent neuronal damage</td>
            <td>Antiepileptics (phenytoin, valproate, levetiracetam)</td>
        </tr>
        <tr>
            <td><strong class="seizure-orange">Refractory</strong></td>
            <td>>60 minutes</td>
            <td>Neuronal death, blood-brain barrier breakdown, cerebral edema</td>
            <td>ICU management, burst suppression</td>
            <td>Anesthetics (propofol, midazolam, thiopental)</td>
        </tr>
        <tr>
            <td><strong class="seizure-orange">Super-refractory</strong></td>
            <td>>24 hours</td>
            <td>Failure to respond to anesthetic agents</td>
            <td>Experimental therapies, ketamine, immunomodulation</td>
            <td>Ketamine, inhalational anesthetics, hypothermia</td>
        </tr>
    </tbody>
</table>

<h3>1.2 Status Epilepticus Management Algorithm</h3>

<div class="status-epilepticus-box">
    <strong>‚ö° STATUS EPILEPTICUS PROTOCOL (0-30 MINUTES):</strong><br>
    <br>
    <strong>0-5 MINUTES (STABILIZE):</strong><br>
    ‚Ä¢ ABCDE approach<br>
    ‚Ä¢ Oxygen via non-rebreather mask<br>
    ‚Ä¢ IV access (x2 large bore)<br>
    ‚Ä¢ Check glucose (fingerstick) ‚Üí Give thiamine 100mg IV + glucose if hypoglycemic<br>
    ‚Ä¢ Monitor: ECG, SpO‚ÇÇ, BP<br>
    <br>
    <strong>5-20 MINUTES (FIRST-LINE TREATMENT):</strong><br>
    ‚Ä¢ <strong class="seizure-orange">Benzodiazepine FIRST (choose one):</strong><br>
    &nbsp;&nbsp;‚Ä¢ Lorazepam 0.1 mg/kg IV (max 4 mg) over 2-5 min OR<br>
    &nbsp;&nbsp;‚Ä¢ Midazolam 0.2 mg/kg IM (max 10 mg) if no IV access OR<br>
    &nbsp;&nbsp;‚Ä¢ Diazepam 0.15 mg/kg IV (max 10 mg)<br>
    ‚Ä¢ Repeat same dose in 5-10 minutes if seizure continues<br>
    <br>
    <strong>20-40 MINUTES (SECOND-LINE TREATMENT):</strong><br>
    ‚Ä¢ <strong class="seizure-orange">Second antiepileptic (choose one):</strong><br>
    &nbsp;&nbsp;‚Ä¢ Fosphenytoin 20 mg PE/kg IV at 150 mg PE/min OR<br>
    &nbsp;&nbsp;‚Ä¢ Valproate 40 mg/kg IV over 10 min OR<br>
    &nbsp;&nbsp;‚Ä¢ Levetiracetam 60 mg/kg IV over 15 min (max 4500 mg)<br>
    <br>
    <strong>>40 MINUTES (REFACTORY STATUS):</strong><br>
    ‚Ä¢ <strong class="seizure-orange">ICU TRANSFER:</strong><br>
    &nbsp;&nbsp;‚Ä¢ RSI with anesthetic agent (propofol/thiopental)<br>
    &nbsp;&nbsp;‚Ä¢ Continuous EEG monitoring<br>
    &nbsp;&nbsp;‚Ä¢ Burst suppression target<br>
    &nbsp;&nbsp;‚Ä¢ Consider ketamine infusion
</div>

<!-- CHAPTER 2: DRUG 1 - DIAZEPAM -->
<div class="page-break"></div>
<h2><span class="chapter-number">2</span> Core Drug 1: Diazepam</h2>

<div class="drug-template">
    <h4>DIAZEPAM - RAPID-ONSET, LONG-ACTING BENZODIAZEPINE</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Benzodiazepine (long-acting)
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Potentiates GABA activity by binding to GABA-A receptor<br>
        ‚Ä¢ Increases frequency of chloride channel opening ‚Üí neuronal hyperpolarization<br>
        ‚Ä¢ Central muscle relaxant effect (acts on spinal cord)<br>
        ‚Ä¢ Anticonvulsant, anxiolytic, sedative, amnestic properties<br>
        ‚Ä¢ Highly lipophilic ‚Üí rapid CNS penetration but also rapid redistribution
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Acute seizure control (status epilepticus)<br>
        ‚Ä¢ Alcohol withdrawal seizures and delirium tremens<br>
        ‚Ä¢ Muscle spasm (tetanus, spasticity)<br>
        ‚Ä¢ Procedural sedation (especially in children)<br>
        ‚Ä¢ Anxiety/agitation (though lorazepam often preferred)<br>
        ‚Ä¢ Benzodiazepine withdrawal
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Severe respiratory depression<br>
        ‚Ä¢ Acute narrow-angle glaucoma<br>
        ‚Ä¢ Severe hepatic impairment<br>
        ‚Ä¢ Sleep apnea (relative)<br>
        ‚Ä¢ Myasthenia gravis (relative - muscle weakness)<br>
        ‚Ä¢ Pregnancy (especially first trimester - teratogenic)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="sedation-blue">Status epilepticus:</strong> 5-10 mg IV over 2-5 min, repeat every 10-15 min (max 30 mg)<br>
        ‚Ä¢ <strong class="sedation-blue">Alcohol withdrawal:</strong> 5-10 mg IV/PO, repeat hourly until calm (symptom-triggered)<br>
        ‚Ä¢ <strong class="sedation-blue">Muscle spasm:</strong> 2-10 mg IV/IM, then 2-10 mg PO TID-QID<br>
        ‚Ä¢ <strong class="sedation-blue">Anxiety/agitation:</strong> 2-10 mg IV/IM/PO, repeat in 3-4 hours if needed<br>
        ‚Ä¢ <strong class="sedation-blue">Procedural sedation:</strong> 5-10 mg IV 5-10 min before procedure
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="sedation-blue">Status epilepticus:</strong> 0.1-0.3 mg/kg IV (max 10 mg) over 2-5 min<br>
        ‚Ä¢ <strong class="sedation-blue">Febrile seizures:</strong> 0.2-0.5 mg/kg PR (rectal gel) if no IV<br>
        ‚Ä¢ <strong class="sedation-blue">Procedural sedation:</strong> 0.2-0.3 mg/kg IV (max 10 mg)<br>
        ‚Ä¢ <strong class="sedation-blue">Muscle spasm:</strong> 0.12-0.8 mg/kg/day PO divided TID-QID
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="sedation-blue">Routes:</strong> IV (preferred for emergencies), IM, PO, PR (rectal)<br>
        ‚Ä¢ <strong class="sedation-blue">Preparation:</strong> 5 mg/mL or 10 mg/2 mL ampoules<br>
        ‚Ä¢ For IV: Give slowly (5 mg/min) to avoid respiratory depression<br>
        ‚Ä¢ For IM: Painful, erratic absorption - avoid if possible<br>
        ‚Ä¢ Rectal gel (Diastat¬Æ): 2.5, 5, 10, 15, 20 mg prefilled syringes<br>
        ‚Ä¢ <strong>Diluent warning:</strong> Contains propylene glycol - risk of toxicity with high doses
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Drowsiness, fatigue, ataxia<br>
        ‚Ä¢ Confusion (especially in elderly)<br>
        ‚Ä¢ Dizziness, vertigo<br>
        ‚Ä¢ Amnesia (anterograde)<br>
        ‚Ä¢ Slurred speech<br>
        ‚Ä¢ Hypotension (especially with rapid IV)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Respiratory depression/arrest (especially with opioids)<br>
        ‚Ä¢ Paradoxical reactions (agitation, aggression)<br>
        ‚Ä¢ Dependence and withdrawal syndrome<br>
        ‚Ä¢ Propylene glycol toxicity (high IV doses): acidosis, hemolysis, renal failure<br>
        ‚Ä¢ Hepatic encephalopathy in cirrhosis<br>
        ‚Ä¢ Teratogenicity (cleft palate if used in first trimester)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="sedation-blue">Opioids, alcohol, other CNS depressants:</strong> Potentiates respiratory depression<br>
        ‚Ä¢ <strong class="sedation-blue">Enzyme inducers (phenytoin, carbamazepine):</strong> Increased metabolism<br>
        ‚Ä¢ <strong class="sedation-blue">Enzyme inhibitors (cimetidine, fluoxetine):</strong> Increased levels<br>
        ‚Ä¢ <strong class="sedation-blue">Theophylline:</strong> May antagonize sedative effect<br>
        ‚Ä¢ <strong class="sedation-blue">Probenecid:</strong> Slows metabolism<br>
        ‚Ä¢ <strong class="sedation-blue">Digoxin:</strong> Increased digoxin levels
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="sedation-blue">Rapid redistribution:</strong> Initial effect lasts 15-30 minutes, but drug persists for days<br>
        ‚Ä¢ <strong class="sedation-blue">Active metabolites:</strong> Nordiazepam has 50-100 hour half-life ‚Üí prolonged sedation<br>
        ‚Ä¢ <strong class="sedation-blue">For status epilepticus:</strong> Lorazepam preferred (longer duration in brain)<br>
        ‚Ä¢ <strong class="sedation-blue">Rectal route:</strong> Useful for children with seizures when IV not available<br>
        ‚Ä¢ <strong class="sedation-blue">Propylene glycol:</strong> Max 1 mg/kg/min to avoid toxicity (50 mg/mL contains 40% PG)<br>
        ‚Ä¢ <strong class="sedation-blue">Flumazenil caution:</strong> Can precipitate seizures in epileptics or benzodiazepine-dependent patients<br>
        ‚Ä¢ <strong class="sedation-blue">Elderly:</strong> Start with half dose, increased sensitivity<br>
        ‚Ä¢ <strong class="sedation-blue">Storage:</strong> Protect from light, refrigerate rectal gel
    </div>
</div>

<div class="clinical-pearl">
    <strong>üß† DIAZEPAM vs LORAZEPAM for SEIZURES:</strong><br>
    ‚Ä¢ <strong>Diazepam:</strong> Faster brain penetration (2 min) but rapid redistribution out of brain (15-30 min duration)<br>
    ‚Ä¢ <strong>Lorazepam:</strong> Slower brain entry (5 min) but stays in brain longer (12-24 hours)<br>
    ‚Ä¢ <em>For status epilepticus: Lorazepam is first choice if available</em>
</div>

<!-- CHAPTER 3: DRUG 2 - MIDAZOLAM -->
<div class="page-break"></div>
<h2><span class="chapter-number">3</span> Core Drug 2: Midazolam</h2>

<div class="drug-template">
    <h4>MIDAZOLAM - WATER-SOLUBLE, SHORT-ACTING BENZODIAZEPINE</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Benzodiazepine (short-acting), imidazobenzodiazepine
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Binds GABA-A receptor ‚Üí increases chloride conductance ‚Üí neuronal hyperpolarization<br>
        ‚Ä¢ Water-soluble at acidic pH (in vial), becomes highly lipophilic at physiological pH ‚Üí rapid CNS penetration<br>
        ‚Ä¢ More potent than diazepam (3-4 times)<br>
        ‚Ä¢ Anticonvulsant, anxiolytic, sedative, amnestic properties<br>
        ‚Ä¢ No active metabolites (unlike other benzodiazepines)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Status epilepticus (especially when no IV access - IM route)<br>
        ‚Ä¢ Procedural sedation (endoscopy, cardioversion, fracture reduction)<br>
        ‚Ä¢ Induction of anesthesia (adjunct)<br>
        ‚Ä¢ Sedation in mechanically ventilated patients (ICU)<br>
        ‚Ä¢ Premedication before surgery<br>
        ‚Ä¢ Acute agitation (combined with antipsychotic)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Acute narrow-angle glaucoma<br>
        ‚Ä¢ Severe respiratory depression<br>
        ‚Ä¢ Shock, hypotension<br>
        ‚Ä¢ Allergy to benzodiazepines<br>
        ‚Ä¢ Myasthenia gravis (relative)<br>
        ‚Ä¢ Sleep apnea (relative)<br>
        ‚Ä¢ Pregnancy (relative - crosses placenta)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="sedation-blue">Status epilepticus (IM):</strong> 10 mg IM (if >40 kg), repeat in 10 min if needed<br>
        ‚Ä¢ <strong class="sedation-blue">Status epilepticus (IV):</strong> 0.1-0.2 mg/kg IV (max 10 mg), repeat every 5-10 min<br>
        ‚Ä¢ <strong class="sedation-blue">Procedural sedation:</strong> 1-2.5 mg IV slow push, titrate every 2-3 min (usual total 2.5-7.5 mg)<br>
        ‚Ä¢ <strong class="sedation-blue">ICU sedation:</strong> 0.02-0.1 mg/kg/hr infusion<br>
        ‚Ä¢ <strong class="sedation-blue">Premedication:</strong> 0.07-0.08 mg/kg IM 30-60 min pre-op<br>
        ‚Ä¢ <strong class="sedation-blue">Acute agitation:</strong> 2.5-5 mg IM with haloperidol 5-10 mg
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="sedation-blue">Status epilepticus:</strong> 0.2 mg/kg IM (max 10 mg) OR 0.15 mg/kg IV (max 10 mg)<br>
        ‚Ä¢ <strong class="sedation-blue">Procedural sedation:</strong> 0.05-0.1 mg/kg IV, titrate (max 0.4 mg/kg total)<br>
        ‚Ä¢ <strong class="sedation-blue">ICU sedation:</strong> 0.05-0.2 mg/kg loading, then 0.06-0.12 mg/kg/hr<br>
        ‚Ä¢ <strong class="sedation-blue">Premedication:</strong> 0.25-0.5 mg/kg PO (max 20 mg) or 0.1-0.15 mg/kg IM
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="sedation-blue">Routes:</strong> IV, IM, PO, intranasal, buccal, rectal<br>
        ‚Ä¢ <strong class="sedation-blue">Preparation:</strong> 1 mg/mL, 5 mg/mL (for injection); 2 mg/mL syrup (PO)<br>
        ‚Ä¢ For IV: Give slowly over 2-5 minutes (respiratory depression risk)<br>
        ‚Ä¢ For IM: Well absorbed (unlike diazepam) - use deltoid or vastus lateralis<br>
        ‚Ä¢ Intranasal: 0.2-0.5 mg/kg (max 10 mg) - use mucosal atomizer device<br>
        ‚Ä¢ Compatible with most IV fluids but may precipitate with alkaline solutions
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Respiratory depression (dose-related)<br>
        ‚Ä¢ Hypotension (especially with opioids)<br>
        ‚Ä¢ Hiccups (common with IV administration)<br>
        ‚Ä¢ Paradoxical reactions (agitation, especially in children/elderly)<br>
        ‚Ä¢ Nausea, vomiting<br>
        ‚Ä¢ Headache, dizziness
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Apnea, respiratory arrest<br>
        ‚Ä¢ Severe hypotension, cardiac arrest<br>
        ‚Ä¢ Anaphylaxis (rare)<br>
        ‚Ä¢ Propylene glycol toxicity with high-dose infusions (similar to diazepam)<br>
        ‚Ä¢ Withdrawal seizures with abrupt discontinuation after prolonged infusion<br>
        ‚Ä¢ Tolerance with long-term use
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="sedation-blue">Opioids:</strong> Synergistic respiratory depression (reduce doses by 30-50%)<br>
        ‚Ä¢ <strong class="sedation-blue">Protease inhibitors (ritonavir):</strong> Markedly increased levels<br>
        ‚Ä¢ <strong class="sedation-blue">Erythromycin, diltiazem, verapamil:</strong> Increased levels<br>
        ‚Ä¢ <strong class="sedation-blue">Theophylline:</strong> May antagonize sedative effect<br>
        ‚Ä¢ <strong class="sedation-blue">Alcohol, other CNS depressants:</strong> Additive effects<br>
        ‚Ä¢ <strong class="sedation-blue">Flumazenil:</strong> Antagonizes effects
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="sedation-blue">IM route advantage:</strong> Well absorbed, rapid onset (5-15 min) - excellent for status epilepticus without IV<br>
        ‚Ä¢ <strong class="sedation-blue">Half-life:</strong> 1.5-3.5 hours (short) - ideal for procedural sedation<br>
        ‚Ä¢ <strong class="sedation-blue">Context-sensitive half-time:</strong> Increases with prolonged infusion (accumulates)<br>
        ‚Ä¢ <strong class="sedation-blue">No active metabolites</strong> - better for elderly, liver disease<br>
        ‚Ä¢ <strong class="sedation-blue">Blue urine:</strong> May turn urine blue-green (normal, from dye)<br>
        ‚Ä¢ <strong class="sedation-blue">For RSI:</strong> Often used with ketamine or etomidate (0.1-0.3 mg/kg)<br>
        ‚Ä¢ <strong class="sedation-blue">Pediatric sedation:</strong> Intranasal route popular for laceration repair (0.2-0.3 mg/kg)<br>
        ‚Ä¢ <strong class="sedation-blue">ICU sedation:</strong> Monitor for propylene glycol toxicity with high doses (>1 mg/kg/hr)
    </div>
</div>

<!-- CHAPTER 4: DRUG 3 - LORAZEPAM -->
<div class="page-break"></div>
<h2><span class="chapter-number">4</span> Core Drug 3: Lorazepam</h2>

<div class="drug-template">
    <h4>LORAZEPAM - FIRST-LINE FOR STATUS EPILEPTICUS</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Benzodiazepine (intermediate-acting)
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Binds GABA-A receptor at Œ±-Œ≥ subunit interface ‚Üí enhances GABA effects<br>
        ‚Ä¢ Increases chloride influx ‚Üí neuronal hyperpolarization ‚Üí reduced excitability<br>
        ‚Ä¢ Less lipophilic than diazepam ‚Üí slower brain entry but longer duration in CNS<br>
        ‚Ä¢ No active metabolites (unlike diazepam)<br>
        ‚Ä¢ Anticonvulsant, anxiolytic, sedative, amnestic properties
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ <strong class="seizure-orange">First-line for status epilepticus</strong> (evidence-based)<br>
        ‚Ä¢ Alcohol withdrawal seizures and delirium tremens<br>
        ‚Ä¢ Anxiety/agitation (especially in medically ill patients)<br>
        ‚Ä¢ Chemotherapy-induced nausea/vomiting (adjunct)<br>
        ‚Ä¢ Premedication before surgery or procedures<br>
        ‚Ä¢ Insomnia (short-term)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Severe respiratory depression<br>
        ‚Ä¢ Sleep apnea (especially untreated)<br>
        ‚Ä¢ Acute narrow-angle glaucoma<br>
        ‚Ä¢ Severe hepatic impairment (may precipitate encephalopathy)<br>
        ‚Ä¢ Myasthenia gravis (relative)<br>
        ‚Ä¢ Pregnancy (especially first trimester)<br>
        ‚Ä¢ Allergy to benzodiazepines or polyethylene glycol
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="seizure-orange">Status epilepticus:</strong> 0.1 mg/kg IV (max 4 mg) over 2-5 min, repeat in 5-10 min if needed<br>
        ‚Ä¢ <strong class="seizure-orange">Alcohol withdrawal:</strong> 1-4 mg IV/PO, repeat every 1-2 hours until calm (CIWA protocol)<br>
        ‚Ä¢ <strong class="seizure-orange">Anxiety/agitation:</strong> 0.5-2 mg IV/IM/PO, repeat every 4-6 hours as needed<br>
        ‚Ä¢ <strong class="seizure-orange">Premedication:</strong> 0.05 mg/kg IM (max 4 mg) 2 hours pre-op<br>
        ‚Ä¢ <strong class="seizure-orange">Chemotherapy N/V:</strong> 1.5 mg/m¬≤ IV (max 3 mg) before chemotherapy
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="seizure-orange">Status epilepticus:</strong> 0.1 mg/kg IV (max 4 mg) over 2-5 min<br>
        ‚Ä¢ <strong class="seizure-orange">Anxiety/premedication:</strong> 0.05 mg/kg PO/IV (max 2 mg)<br>
        ‚Ä¢ <strong class="seizure-orange">Insomnia:</strong> 0.05 mg/kg PO at bedtime (max 2 mg)<br>
        ‚Ä¢ <strong class="seizure-orange">Chemotherapy N/V:</strong> 0.05 mg/kg IV before chemo
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="seizure-orange">Routes:</strong> IV (preferred for emergencies), IM, PO, sublingual<br>
        ‚Ä¢ <strong class="seizure-orange">Preparation:</strong> 2 mg/mL or 4 mg/mL vials; 0.5, 1, 2 mg tablets<br>
        ‚Ä¢ For IV: Dilute with equal volume of sterile water/NS, give over 2-5 minutes<br>
        ‚Ä¢ For IM: Well absorbed but slower onset than IV (15-30 min)<br>
        ‚Ä¢ Contains polyethylene glycol and benzyl alcohol (caution in neonates)<br>
        ‚Ä¢ Stable for 24 hours when diluted
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Sedation, drowsiness<br>
        ‚Ä¢ Dizziness, ataxia (especially in elderly)<br>
        ‚Ä¢ Weakness<br>
        ‚Ä¢ Amnesia (desirable for procedures)<br>
        ‚Ä¢ Blurred vision<br>
        ‚Ä¢ Paradoxical reactions (rare)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Respiratory depression/arrest (especially with opioids)<br>
        ‚Ä¢ Hypotension (with rapid IV administration)<br>
        ‚Ä¢ Hepatic encephalopathy in cirrhosis<br>
        ‚Ä¢ Benzodiazepine withdrawal syndrome<br>
        ‚Ä¢ Dependence with long-term use<br>
        ‚Ä¢ Propylene glycol toxicity with high doses (similar to diazepam)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="seizure-orange">Opioids, alcohol, other CNS depressants:</strong> Potentiates respiratory depression<br>
        ‚Ä¢ <strong class="seizure-orange">Valproate:</strong> May increase lorazepam levels<br>
        ‚Ä¢ <strong class="seizure-orange">Probenecid:</strong> Increases levels by inhibiting glucuronidation<br>
        ‚Ä¢ <strong class="seizure-orange">Oral contraceptives:</strong> May increase levels<br>
        ‚Ä¢ <strong class="seizure-orange">Theophylline:</strong> May reduce sedative effect<br>
        ‚Ä¢ <strong class="seizure-orange">Flumazenil:</strong> Reverses effects (use with caution in epilepsy)
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="seizure-orange">FIRST CHOICE for status epilepticus</strong> - longer duration in brain than diazepam<br>
        ‚Ä¢ <strong class="seizure-orange">Onset:</strong> 2-5 minutes IV, duration 12-24 hours for seizure control<br>
        ‚Ä¢ <strong class="seizure-orange">No active metabolites</strong> - safer in elderly, liver disease<br>
        ‚Ä¢ <strong class="seizure-orange">Alcohol withdrawal:</strong> Preferred due to longer duration, less abuse potential<br>
        ‚Ä¢ <strong class="seizure-orange">CIWA protocol:</strong> Symptom-triggered dosing reduces total benzodiazepine use<br>
        ‚Ä¢ <strong class="seizure-orange">IM absorption:</strong> Good but slower (15-30 min) - not ideal for status epilepticus<br>
        ‚Ä¢ <strong class="seizure-orange">Stability:</strong> Degrades rapidly in plastic syringes - draw up just before use<br>
        ‚Ä¢ <strong class="seizure-orange">Sublingual:</strong> Good alternative when IV/IM not possible (80% bioavailability)
    </div>
</div>

<div class="clinical-pearl">
    <strong>üß† BENZODIAZEPINE COMPARISON FOR STATUS EPILEPTICUS:</strong><br>
    ‚Ä¢ <strong>Lorazepam:</strong> Onset 2-5 min, duration 12-24h - FIRST CHOICE<br>
    ‚Ä¢ <strong>Midazolam (IM):</strong> Onset 5-15 min, duration 1-2h - BEST if no IV access<br>
    ‚Ä¢ <strong>Diazepam:</strong> Onset 2 min, duration 15-30 min - rapid but short (needs second agent)
</div>

<!-- CHAPTER 5: DRUG 4 - PHENYTOIN / FOSPHENYTOIN -->
<div class="page-break"></div>
<h2><span class="chapter-number">5</span> Core Drug 4: Phenytoin / Fosphenytoin</h2>

<div class="drug-template">
    <h4>PHENYTOIN & FOSPHENYTOIN - SECOND-LINE FOR STATUS EPILEPTICUS</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Hydantoin anticonvulsant (phenytoin); phosphate ester prodrug (fosphenytoin)
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Blocks voltage-dependent sodium channels ‚Üí reduces neuronal excitability<br>
        ‚Ä¢ Inhibits high-frequency repetitive firing of neurons (use-dependent blockade)<br>
        ‚Ä¢ Stabilizes neuronal membranes<br>
        ‚Ä¢ May also affect calcium channels and neurotransmitter release<br>
        ‚Ä¢ <strong>Fosphenytoin:</strong> Water-soluble prodrug converted to phenytoin by phosphatases
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Status epilepticus (second-line after benzodiazepines)<br>
        ‚Ä¢ Prophylaxis/treatment of tonic-clonic and partial seizures<br>
        ‚Ä¢ Neurosurgical prophylaxis (post-craniotomy)<br>
        ‚Ä¢ Trigeminal neuralgia (second-line)<br>
        ‚Ä¢ Digitalis-induced arrhythmias (historical use)<br>
        ‚Ä¢ <strong>Fosphenytoin preferred</strong> due to better safety profile
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Sinus bradycardia, SA block, AV block<br>
        ‚Ä¢ Adams-Stokes syndrome<br>
        ‚Ä¢ Hypersensitivity to phenytoin, fosphenytoin, or other hydantoins<br>
        ‚Ä¢ Pregnancy (teratogenic - fetal hydantoin syndrome)<br>
        ‚Ä¢ Relative: Hepatic impairment, porphyria
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="neuro-purple">Status epilepticus (phenytoin):</strong> 20 mg/kg IV at max 50 mg/min<br>
        ‚Ä¢ <strong class="neuro-purple">Status epilepticus (fosphenytoin):</strong> 20 mg PE/kg IV at 150 mg PE/min<br>
        ‚Ä¢ <strong class="neuro-purple">Loading (non-emergent):</strong> 15-20 mg/kg IV/PO<br>
        ‚Ä¢ <strong class="neuro-purple">Maintenance:</strong> 300-400 mg/day PO/IV (5 mg/kg/day)<br>
        ‚Ä¢ <strong class="neuro-purple">Therapeutic level:</strong> 10-20 mg/L (toxic >20 mg/L)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="neuro-purple">Status epilepticus:</strong> 20 mg/kg IV (phenytoin) or 20 mg PE/kg (fosphenytoin)<br>
        ‚Ä¢ <strong class="neuro-purple">Loading:</strong> 15-20 mg/kg<br>
        ‚Ä¢ <strong class="neuro-purple">Maintenance:</strong> 5-10 mg/kg/day divided BID-TID<br>
        ‚Ä¢ <strong class="neuro-purple">Neonates:</strong> Loading 15-20 mg/kg, maintenance 4-8 mg/kg/day
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="neuro-purple">Phenytoin:</strong> IV ONLY (never IM - painful, erratic absorption)<br>
        ‚Ä¢ <strong class="neuro-purple">Fosphenytoin:</strong> IV or IM (well tolerated IM)<br>
        ‚Ä¢ <strong class="neuro-purple">Phenytoin IV:</strong> Dilute in NS only (precipitates in dextrose)<br>
        ‚Ä¢ <strong class="neuro-purple">Infusion rate:</strong> Phenytoin max 50 mg/min, fosphenytoin max 150 mg PE/min<br>
        ‚Ä¢ <strong class="neuro-purple">IM fosphenytoin:</strong> Divide dose into multiple sites if >10 mL total
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Nystagmus (earliest sign of toxicity)<br>
        ‚Ä¢ Ataxia, dizziness<br>
        ‚Ä¢ Slurred speech<br>
        ‚Ä¢ Gingival hyperplasia (chronic use)<br>
        ‚Ä¢ Hirsutism (chronic use)<br>
        ‚Ä¢ Coarsening of facial features (chronic use)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Cardiovascular collapse (with rapid IV phenytoin - "purple glove syndrome")<br>
        ‚Ä¢ Stevens-Johnson syndrome, toxic epidermal necrolysis<br>
        ‚Ä¢ Drug rash with eosinophilia and systemic symptoms (DRESS)<br>
        ‚Ä¢ Hepatotoxicity<br>
        ‚Ä¢ Blood dyscrasias (aplastic anemia, agranulocytosis)<br>
        ‚Ä¢ Cerebellar atrophy with chronic toxicity<br>
        ‚Ä¢ Teratogenicity (fetal hydantoin syndrome)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="neuro-purple">Warfarin:</strong> Complex interaction (monitor INR)<br>
        ‚Ä¢ <strong class="neuro-purple">Oral contraceptives:</strong> Reduced efficacy<br>
        ‚Ä¢ <strong class="neuro-purple">Isoniazid, chloramphenicol, cimetidine:</strong> Increased levels<br>
        ‚Ä¢ <strong class="neuro-purple">Carbamazepine, phenobarbital:</strong> Decreased levels<br>
        ‚Ä¢ <strong class="neuro-purple">Valproate:</strong> Displaces from protein binding, complex interaction<br>
        ‚Ä¢ <strong class="neuro-purple">Alcohol:</strong> Acute use increases levels, chronic decreases
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="neuro-purple">FOSPHENYTOIN PREFERRED:</strong> Water-soluble, can give faster, IM option, less tissue damage<br>
        ‚Ä¢ <strong class="neuro-purple">Purple glove syndrome:</strong> Limb edema, discoloration, pain with phenytoin extravasation<br>
        ‚Ä¢ <strong class="neuro-purple">PE = Phenytoin Equivalent:</strong> 1.5 mg fosphenytoin = 1 mg phenytoin<br>
        ‚Ä¢ <strong class="neuro-purple">Therapeutic monitoring:</strong> Check level 2 hours after IV load, then periodically<br>
        ‚Ä¢ <strong class="neuro-purple">Non-linear kinetics:</strong> Small dose increases can cause large level increases<br>
        ‚Ä¢ <strong class="neuro-purple">Free vs total levels:</strong> Measure free phenytoin in renal failure, hypoalbuminemia<br>
        ‚Ä¢ <strong class="neuro-purple">Half-life:</strong> 24 hours initially, increases with chronic use (up to 60 hours)<br>
        ‚Ä¢ <strong class="neuro-purple">Antidote for overdose:</strong> Multiple-dose activated charcoal, supportive care
    </div>
</div>

<div class="warning-box">
    <strong>‚ö†Ô∏è PHENYTOIN WARNING:</strong> IV phenytoin can cause cardiovascular collapse if given too fast. Monitor ECG and BP continuously during infusion. Use fosphenytoin if available - safer and faster administration.
</div>

<!-- CHAPTER 6: DRUG 5 - PHENOBARBITAL -->
<div class="page-break"></div>
<h2><span class="chapter-number">6</span> Core Drug 5: Phenobarbital</h2>

<div class="drug-template">
    <h4>PHENOBARBITAL - OLD BUT EFFECTIVE ANTICONVULSANT</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Barbiturate (long-acting)
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Potentiates GABA activity by increasing chloride channel opening duration<br>
        ‚Ä¢ Also has direct GABA-mimetic effect at high doses<br>
        ‚Ä¢ Reduces glutamate-induced excitotoxicity<br>
        ‚Ä¢ Suppresses neuronal excitability throughout CNS<br>
        ‚Ä¢ Induces hepatic microsomal enzymes (P450 induction)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Refractory status epilepticus (third-line)<br>
        ‚Ä¢ Neonatal seizures (first-line in some centers)<br>
        ‚Ä¢ Alcohol withdrawal (severe cases)<br>
        ‚Ä¢ Sedation in mechanically ventilated patients (historical)<br>
        ‚Ä¢ Prevention of seizures in eclampsia (with magnesium)<br>
        ‚Ä¢ Hyperbilirubinemia in neonates (enzyme induction)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Acute intermittent porphyria<br>
        ‚Ä¢ Severe respiratory depression<br>
        ‚Ä¢ Severe hepatic impairment<br>
        ‚Ä¢ Hypersensitivity to barbiturates<br>
        ‚Ä¢ Pregnancy (relative - neonatal withdrawal)<br>
        ‚Ä¢ Myasthenia gravis (relative)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="neuro-purple">Status epilepticus:</strong> 20 mg/kg IV at 50-100 mg/min<br>
        ‚Ä¢ <strong class="neuro-purple">May repeat:</strong> 5-10 mg/kg every 15-30 min (max total 30-40 mg/kg)<br>
        ‚Ä¢ <strong class="neuro-purple">Alcohol withdrawal:</strong> 130-260 mg IV/IM, then 30-60 mg TID-QID<br>
        ‚Ä¢ <strong class="neuro-purple">Maintenance:</strong> 1-3 mg/kg/day (60-200 mg/day)<br>
        ‚Ä¢ <strong class="neuro-purple">Therapeutic level:</strong> 15-40 mg/L (toxic >40 mg/L)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="neuro-purple">Status epilepticus:</strong> 20 mg/kg IV at 1-2 mg/kg/min<br>
        ‚Ä¢ <strong class="neuro-purple">Neonatal seizures:</strong> 20 mg/kg IV load, then 3-5 mg/kg/day<br>
        ‚Ä¢ <strong class="neuro-purple">Maintenance:</strong> 3-8 mg/kg/day divided BID<br>
        ‚Ä¢ <strong class="neuro-purple">Hyperbilirubinemia:</strong> 5-10 mg/kg/day √ó 3-7 days
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="neuro-purple">Routes:</strong> IV (preferred), IM, PO<br>
        ‚Ä¢ <strong class="neuro-purple">Preparation:</strong> 30 mg/mL, 60 mg/mL, 130 mg/mL ampoules<br>
        ‚Ä¢ For IV: Dilute in equal volume of sterile water, give slowly (max 100 mg/min)<br>
        ‚Ä¢ IM: Painful, can cause sterile abscess - avoid if possible<br>
        ‚Ä¢ Contains propylene glycol (risk of toxicity with rapid infusion)<br>
        ‚Ä¢ Compatible with most IV solutions but best in NS
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Sedation, drowsiness, lethargy<br>
        ‚Ä¢ Ataxia, nystagmus<br>
        ‚Ä¢ Cognitive impairment<br>
        ‚Ä¢ Respiratory depression (dose-related)<br>
        ‚Ä¢ Hypotension (especially with rapid IV)<br>
        ‚Ä¢ Enzyme induction (affects many drugs)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Severe respiratory depression/apnea<br>
        ‚Ä¢ Cardiovascular collapse<br>
        ‚Ä¢ Stevens-Johnson syndrome (rare)<br>
        ‚Ä¢ Megaloblastic anemia (chronic use)<br>
        ‚Ä¢ Osteomalacia (chronic use - vitamin D metabolism)<br>
        ‚Ä¢ Dependence and withdrawal syndrome<br>
        ‚Ä¢ Propylene glycol toxicity (high doses)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="neuro-purple">Warfarin, oral contraceptives, steroids:</strong> Reduces efficacy (enzyme induction)<br>
        ‚Ä¢ <strong class="neuro-purple">Valproate:</strong> Increases phenobarbital levels<br>
        ‚Ä¢ <strong class="neuro-purple">Alcohol, benzodiazepines, opioids:</strong> Additive CNS depression<br>
        ‚Ä¢ <strong class="neuro-purple">Theophylline:</strong> Reduced levels<br>
        ‚Ä¢ <strong class="neuro-purple">Chloramphenicol, isoniazid:</strong> Increased phenobarbital levels<br>
        ‚Ä¢ <strong class="neuro-purple">Doxycycline:</strong> Reduced levels
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="neuro-purple">For refractory status:</strong> Often requires intubation and ventilation<br>
        ‚Ä¢ <strong class="neuro-purple">Onset:</strong> 5 minutes IV, peak 30 minutes<br>
        ‚Ä¢ <strong class="neuro-purple">Half-life:</strong> 80-120 hours (long!) - accumulates with repeated doses<br>
        ‚Ä¢ <strong class="neuro-purple">Neonates:</strong> First-line in some centers (better evidence than phenytoin)<br>
        ‚Ä¢ <strong class="neuro-purple">Therapeutic monitoring:</strong> Check levels 2-4 hours after load, then weekly<br>
        ‚Ä¢ <strong class="neuro-purple">Withdrawal:</strong> Taper slowly over weeks to avoid seizures<br>
        ‚Ä¢ <strong class="neuro-purple">Cost:</strong> Very inexpensive compared to newer agents<br>
        ‚Ä¢ <strong class="neuro-purple">Propylene glycol:</strong> Max 1 mg/kg/min to avoid toxicity (similar to diazepam)
    </div>
</div>

<!-- CHAPTER 7: DRUG 6 - MANNITOL -->
<div class="page-break"></div>
<h2><span class="chapter-number">7</span> Core Drug 6: Mannitol</h2>

<div class="drug-template">
    <h4>MANNITOL - OSMOTIC AGENT FOR RAISED ICP</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Osmotic diuretic, sugar alcohol
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Creates osmotic gradient ‚Üí draws water from brain tissue into plasma<br>
        ‚Ä¢ Reduces brain volume and intracranial pressure (ICP)<br>
        ‚Ä¢ Improves cerebral perfusion pressure (CPP = MAP - ICP)<br>
        ‚Ä¢ Free radical scavenger (neuroprotective)<br>
        ‚Ä¢ Induces diuresis by osmotic effect in renal tubules<br>
        ‚Ä¢ May improve blood rheology (reduces blood viscosity)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Raised intracranial pressure (traumatic brain injury, stroke, tumor)<br>
        ‚Ä¢ Cerebral edema (vasogenic and cytotoxic)<br>
        ‚Ä¢ Prevention/treatment of acute renal failure (especially rhabdomyolysis)<br>
        ‚Ä¢ Glaucoma (to reduce intraocular pressure)<br>
        ‚Ä¢ Diuresis in drug overdose (forced diuresis)<br>
        ‚Ä¢ Diagnostic agent for oliguric renal failure
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Anuria (if not from dehydration)<br>
        ‚Ä¢ Severe pulmonary edema/congestive heart failure<br>
        ‚Ä¢ Active intracranial bleeding (relative - may expand hematoma)<br>
        ‚Ä¢ Severe dehydration<br>
        ‚Ä¢ Metabolic edema (toxic ingestion)<br>
        ‚Ä¢ Hypersensitivity to mannitol
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="neuro-purple">Raised ICP:</strong> 0.25-1 g/kg IV over 20-30 minutes (usual 1 g/kg)<br>
        ‚Ä¢ <strong class="neuro-purple">Repeat doses:</strong> 0.25-0.5 g/kg every 4-8 hours as needed<br>
        ‚Ä¢ <strong class="neuro-purple">Maintenance:</strong> 0.25-0.5 g/kg every 4-6 hours (keep serum osmolality 300-320 mOsm/kg)<br>
        ‚Ä¢ <strong class="neuro-purple">Renal protection:</strong> 25 g IV, then infusion to maintain urine output >100 mL/hr<br>
        ‚Ä¢ <strong class="neuro-purple">Glaucoma:</strong> 1.5-2 g/kg IV over 30-60 minutes
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="neuro-purple">Raised ICP:</strong> 0.25-1 g/kg IV over 20-30 minutes<br>
        ‚Ä¢ <strong class="neuro-purple">Maintenance:</strong> 0.25-0.5 g/kg every 4-8 hours<br>
        ‚Ä¢ <strong class="neuro-purple">Renal protection:</strong> 0.5-1 g/kg, then 0.1-0.2 g/kg/hr<br>
        ‚Ä¢ <strong class="neuro-purple">Test dose:</strong> 0.2 g/kg over 3-5 min to assess renal function
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="neuro-purple">Route:</strong> IV infusion only (never IM or SC)<br>
        ‚Ä¢ <strong class="neuro-purple">Preparation:</strong> 10%, 20%, 25% solutions (10% = 100 mg/mL, 20% = 200 mg/mL)<br>
        ‚Ä¢ Use filter needle to draw up (crystals may form)<br>
        ‚Ä¢ Warm solution to dissolve crystals if present<br>
        ‚Ä¢ Administer through large-bore IV (phlebitis risk)<br>
        ‚Ä¢ Use infusion pump for accurate rate control
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Headache, nausea, vomiting<br>
        ‚Ä¢ Dry mouth, thirst<br>
        ‚Ä¢ Blurred vision<br>
        ‚Ä¢ Pulmonary congestion (fluid shift)<br>
        ‚Ä¢ Diuresis (expected)<br>
        ‚Ä¢ Injection site pain/phlebitis
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Fluid and electrolyte imbalance (dehydration, hypernatremia)<br>
        ‚Ä¢ Congestive heart failure/pulmonary edema (fluid overload)<br>
        ‚Ä¢ Renal failure (osmotic nephrosis)<br>
        ‚Ä¢ Rebound intracranial hypertension<br>
        ‚Ä¢ Cerebral herniation (if given too rapidly with mass lesion)<br>
        ‚Ä¢ Anaphylaxis (rare)<br>
        ‚Ä¢ Rhabdomyolysis (with extravasation)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="neuro-purple">Other diuretics:</strong> Additive effects<br>
        ‚Ä¢ <strong class="neuro-purple">Lithium:</strong> Increased renal excretion<br>
        ‚Ä¢ <strong class="neuro-purple">Digoxin:</strong> Toxicity if hypokalemia occurs<br>
        ‚Ä¢ <strong class="neuro-purple">Nephrotoxic drugs:</strong> Increased risk of renal failure<br>
        ‚Ä¢ <strong class="neuro-purple">Neuromuscular blockers:</strong> May potentiate effects
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="neuro-purple">Monitor:</strong> Serum osmolality (target 300-320 mOsm/kg), electrolytes, urine output<br>
        ‚Ä¢ <strong class="neuro-purple">Osmolar gap:</strong> Useful to monitor effectiveness (measured - calculated osmolality)<br>
        ‚Ä¢ <strong class="neuro-purple">Rebound effect:</strong> May occur as mannitol enters brain - use hypertonic saline as alternative<br>
        ‚Ä¢ <strong class="neuro-purple">Test dose:</strong> Give 0.2 g/kg over 3-5 min, if no diuresis in 2 hours - renal impairment<br>
        ‚Ä¢ <strong class="neuro-purple">For TBI:</strong> Use only if signs of herniation or ICP >20-25 mmHg<br>
        ‚Ä¢ <strong class="neuro-purple">Half-life:</strong> 100 minutes (prolonged in renal failure)<br>
        ‚Ä¢ <strong class="neuro-purple">Hypertonic saline vs mannitol:</strong> Hypertonic saline may have less rebound, better CPP improvement<br>
        ‚Ä¢ <strong class="neuro-purple">Crystallization:</strong> Warm bottle in water bath if crystals present, do not use if cannot dissolve
    </div>
</div>

<div class="icp-alert">
    <strong>üìä RAISED ICP MANAGEMENT:</strong> Mannitol FIRST for signs of herniation ‚Üí Hypertonic saline SECOND ‚Üí Sedation/analgesia ‚Üí Neuromuscular blockade ‚Üí Barbiturate coma ‚Üí Decompressive craniectomy
</div>

<!-- CHAPTER 8: DRUG 7 - HALOPERIDOL -->
<div class="page-break"></div>
<h2><span class="chapter-number">8</span> Core Drug 7: Haloperidol</h2>

<div class="drug-template">
    <h4>HALOPERIDOL - TYPICAL ANTIPSYCHOTIC FOR ACUTE AGITATION</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Typical (first-generation) antipsychotic, butyrophenone
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Potent dopamine D‚ÇÇ receptor antagonist (particularly in mesolimbic pathway)<br>
        ‚Ä¢ Also has some anticholinergic, antihistaminic, and alpha-adrenergic blockade<br>
        ‚Ä¢ Reduces psychotic symptoms, agitation, aggression<br>
        ‚Ä¢ Minimal sedative effects at low doses (unlike phenothiazines)<br>
        ‚Ä¢ Anti-emetic effect (acts on chemoreceptor trigger zone)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Acute agitation/psychosis (often combined with benzodiazepine)<br>
        ‚Ä¢ Delirium (especially hyperactive)<br>
        ‚Ä¢ Chemical restraint for violent patients<br>
        ‚Ä¢ Nausea/vomiting (especially chemotherapy-induced)<br>
        ‚Ä¢ Tourette syndrome, Huntington's chorea<br>
        ‚Ä¢ Intractable hiccups
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Parkinson's disease, Lewy body dementia<br>
        ‚Ä¢ Severe CNS depression, coma<br>
        ‚Ä¢ Hypersensitivity to haloperidol<br>
        ‚Ä¢ QT prolongation, torsades de pointes risk<br>
        ‚Ä¢ Neuroleptic malignant syndrome (from previous antipsychotic)<br>
        ‚Ä¢ Pregnancy (relative - crosses placenta)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="psych-red">Acute agitation IM:</strong> 2-10 mg IM (usual 5 mg), repeat every 30-60 min (max 20 mg/24h)<br>
        ‚Ä¢ <strong class="psych-red">Acute agitation IV:</strong> 0.5-10 mg IV, repeat every 30 min (off-label but common)<br>
        ‚Ä¢ <strong class="psych-red">Delirium:</strong> 0.5-2 mg IV/IM, repeat every 30 min until calm, then scheduled doses<br>
        ‚Ä¢ <strong class="psych-red">Psychosis:</strong> 0.5-5 mg PO BID-TID, increase gradually<br>
        ‚Ä¢ <strong class="psych-red">Nausea:</strong> 1-2 mg IV/IM every 4-8 hours as needed
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="psych-red">Agitation (adolescents):</strong> 0.5-2 mg IM, repeat every 30-60 min<br>
        ‚Ä¢ <strong class="psych-red">Psychosis:</strong> 0.5-5 mg/day PO divided BID-TID<br>
        ‚Ä¢ <strong class="psych-red">Tourette syndrome:</strong> 0.5-2 mg PO BID-TID<br>
        ‚Ä¢ <strong class="psych-red">Not recommended</strong> in children <3 years except for severe conditions
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="psych-red">Routes:</strong> IM (preferred for acute), IV (off-label but common), PO<br>
        ‚Ä¢ <strong class="psych-red">Preparation:</strong> 5 mg/mL ampoule (IM/IV), 0.5, 1, 2, 5, 10, 20 mg tablets<br>
        ‚Ä¢ For IV: Dilute in 50 mL NS or D5W, infuse over 30 minutes<br>
        ‚Ä¢ For IM: Deep injection, massage site<br>
        ‚Ä¢ Lactate vs decanoate: Lactate for acute, decanoate for depot (every 4 weeks)
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Extrapyramidal symptoms (dystonia, akathisia, parkinsonism)<br>
        ‚Ä¢ Sedation (less than phenothiazines)<br>
        ‚Ä¢ Anticholinergic effects (dry mouth, blurred vision, constipation)<br>
        ‚Ä¢ Orthostatic hypotension<br>
        ‚Ä¢ Weight gain (chronic use)<br>
        ‚Ä¢ Hyperprolactinemia (galactorrhea, sexual dysfunction)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Neuroleptic malignant syndrome (NMS) - hyperthermia, rigidity, autonomic instability<br>
        ‚Ä¢ Tardive dyskinesia (chronic use)<br>
        ‚Ä¢ QT prolongation ‚Üí torsades de pointes<br>
        ‚Ä¢ Seizures (lower threshold)<br>
        ‚Ä¢ Agranulocytosis (rare)<br>
        ‚Ä¢ Severe dystonic reactions (especially in young males)<br>
        ‚Ä¢ Withdrawal dyskinesias
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="psych-red">Other CNS depressants:</strong> Additive sedation<br>
        ‚Ä¢ <strong class="psych-red">QT-prolonging drugs:</strong> Increased arrhythmia risk (amiodarone, sotalol, TCAs)<br>
        ‚Ä¢ <strong class="psych-red">Anticholinergics:</strong> May reduce extrapyramidal symptoms but worsen confusion<br>
        ‚Ä¢ <strong class="psych-red">Levodopa, dopamine agonists:</strong> Antagonizes effect<br>
        ‚Ä¢ <strong class="psych-red">Enzyme inducers (carbamazepine, phenytoin):</strong> Reduced levels<br>
        ‚Ä¢ <strong class="psych-red">Enzyme inhibitors (fluoxetine):</strong> Increased levels
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="psych-red">"5 and 2" protocol:</strong> Haloperidol 5 mg IM + Lorazepam 2 mg IM for acute agitation<br>
        ‚Ä¢ <strong class="psych-red">QT monitoring:</strong> Check ECG before and after high doses (>10 mg)<br>
        ‚Ä¢ <strong class="psych-red">Extrapyramidal symptoms:</strong> Treat with benztropine 1-2 mg IM/IV or diphenhydramine 25-50 mg IV<br>
        ‚Ä¢ <strong class="psych-red">NMS treatment:</strong> Stop drug, supportive care, dantrolene or bromocriptine<br>
        ‚Ä¢ <strong class="psych-red">Elderly with dementia:</strong> Increased mortality risk - use lowest effective dose<br>
        ‚Ä¢ <strong class="psych-red">IV use:</strong> More extrapyramidal side effects than IM<br>
        ‚Ä¢ <strong class="psych-red">Half-life:</strong> 12-36 hours (long) - accumulates with repeated dosing<br>
        ‚Ä¢ <strong class="psych-red">Delirium:</strong> Avoid in hypoactive delirium, may worsen confusion
    </div>
</div>

<!-- CHAPTER 9: DRUG 8 - NALOXONE -->
<div class="page-break"></div>
<h2><span class="chapter-number">9</span> Core Drug 8: Naloxone</h2>

<div class="drug-template">
    <h4>NALOXONE - OPIOID ANTAGONIST FOR OVERDOSE</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Competitive opioid receptor antagonist
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Competitive antagonist at mu, kappa, and delta opioid receptors<br>
        ‚Ä¢ Displaces opioids from receptors with high affinity<br>
        ‚Ä¢ Reverses respiratory depression, sedation, hypotension<br>
        ‚Ä¢ No opioid agonist activity (pure antagonist)<br>
        ‚Ä¢ Rapid onset but short duration (shorter than most opioids)<br>
        ‚Ä¢ Also reverses opioid-induced pruritus, urinary retention
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Opioid overdose (respiratory depression, coma)<br>
        ‚Ä¢ Reversal of opioid effects post-operatively<br>
        ‚Ä¢ Diagnostic: Suspected opioid overdose (therapeutic trial)<br>
        ‚Ä¢ Opioid-induced pruritus (low dose)<br>
        ‚Ä¢ Opioid-induced constipation (peripheral acting formulations)<br>
        ‚Ä¢ Neonatal respiratory depression from maternal opioids
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Hypersensitivity to naloxone<br>
        ‚Ä¢ <strong>Note:</strong> No absolute contraindications in opioid overdose (life-saving)<br>
        ‚Ä¢ Relative: Physical dependence on opioids (precipitates withdrawal)<br>
        ‚Ä¢ Cardiac patients (may cause pulmonary edema, arrhythmias)<br>
        ‚Ä¢ Neonates of opioid-dependent mothers (use with caution)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="psych-red">Opioid overdose:</strong> 0.4-2 mg IV/IM/SC, repeat every 2-3 min (max 10 mg)<br>
        ‚Ä¢ <strong class="psych-red">Post-op reversal:</strong> 0.1-0.2 mg IV every 2-3 min to desired effect<br>
        ‚Ä¢ <strong class="psych-red">Infusion:</strong> 2/3 of initial effective dose per hour (e.g., 0.4 mg/hr)<br>
        ‚Ä¢ <strong class="psych-red">Intranasal:</strong> 2 mg (1 mg per nostril) - pre-hospital use<br>
        ‚Ä¢ <strong class="psych-red">Auto-injector:</strong> 0.4 mg IM (Evzio¬Æ) or 2 mg IM (higher dose formulations)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="psych-red">Opioid overdose:</strong> 0.01 mg/kg IV/IM/SC, repeat every 2-3 min (max 2 mg)<br>
        ‚Ä¢ <strong class="psych-red">Neonates:</strong> 0.01 mg/kg IV/IM/SC, repeat every 2-3 min<br>
        ‚Ä¢ <strong class="psych-red">Infusion:</strong> 0.0025-0.16 mg/kg/hr after initial bolus<br>
        ‚Ä¢ <strong class="psych-red">Intranasal:</strong> 2 mg (same as adult - absorption varies)
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="psych-red">Routes:</strong> IV (fastest), IM, SC, intranasal, endotracheal<br>
        ‚Ä¢ <strong class="psych-red">Preparation:</strong> 0.4 mg/mL, 1 mg/mL ampoules<br>
        ‚Ä¢ For IV: Give undiluted, rapid push for overdose, slow titration for post-op<br>
        ‚Ä¢ For infusion: Mix 2 mg in 500 mL D5W or NS = 4 mcg/mL<br>
        ‚Ä¢ Intranasal: Use mucosal atomizer device or prefilled device (Narcan¬Æ)<br>
        ‚Ä¢ Endotracheal: 2-2.5 times IV dose diluted in 5-10 mL NS
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Precipitated opioid withdrawal (agitation, nausea, vomiting, diarrhea)<br>
        ‚Ä¢ Tachycardia, hypertension<br>
        ‚Ä¢ Nausea, vomiting<br>
        ‚Ä¢ Sweating, tremors<br>
        ‚Ä¢ Pulmonary edema (rare, especially in cardiac patients)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Acute opioid withdrawal syndrome (dangerous in opioid-dependent patients)<br>
        ‚Ä¢ Pulmonary edema (non-cardiogenic)<br>
        ‚Ä¢ Ventricular arrhythmias<br>
        ‚Ä¢ Seizures (rare)<br>
        ‚Ä¢ Cardiac arrest (rare, usually in patients with underlying heart disease)<br>
        ‚Ä¢ Hypertension ‚Üí cerebral hemorrhage (especially in hypertensive patients)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="psych-red">Opioid agonists:</strong> Antagonizes effects (obvious)<br>
        ‚Ä¢ <strong class="psych-red">Opioid partial agonists (buprenorphine):</strong> May require higher doses<br>
        ‚Ä¢ <strong class="psych-red">Clonidine:</strong> May precipitate hypertension when reversing opioids<br>
        ‚Ä¢ <strong class="psych-red">Flumazenil:</strong> Used together in mixed overdoses<br>
        ‚Ä¢ Essentially no pharmacodynamic interactions (pure antagonist)
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="psych-red">"Start low, go slow"</strong> in opioid-dependent patients to avoid severe withdrawal<br>
        ‚Ä¢ <strong class="psych-red">Duration:</strong> 30-90 minutes (shorter than most opioids) ‚Üí RE-DOSE OFTEN<br>
        ‚Ä¢ <strong class="psych-red">Long-acting opioids (methadone, fentanyl patches):</strong> May need infusion for 24+ hours<br>
        ‚Ä¢ <strong class="psych-red">Observe period:</strong> At least 4-6 hours after last dose (longer for long-acting opioids)<br>
        ‚Ä¢ <strong class="psych-red">Buprenorphine overdose:</strong> May require high doses (2-10 mg) due to high receptor affinity<br>
        ‚Ä¢ <strong class="psych-red">Intranasal:</strong> Takes 2-5 minutes to work vs 30-60 seconds IV<br>
        ‚Ä¢ <strong class="psych-red">Pulmonary edema:</strong> Treat with oxygen, diuretics, PEEP; usually resolves in 24-48 hours<br>
        ‚Ä¢ <strong class="psych-red">Harm reduction:</strong> Provide take-home naloxone to patients at risk of overdose
    </div>
</div>

<div class="overdose-alert">
    <strong>üíä OPIOID OVERDOSE TRIAD:</strong> 1. Respiratory depression (<12 breaths/min) 2. Pinpoint pupils 3. Decreased consciousness ‚Üí TREAT WITH NALOXONE
</div>

<!-- CHAPTER 10: CONDITION-SPECIFIC MANAGEMENT -->
<div class="page-break"></div>
<h2><span class="chapter-number">10</span> Condition-Specific Management</h2>

<h3>10.1 Status Epilepticus Management Protocol</h3>

<div class="status-epilepticus-box">
    <strong>üïí STATUS EPILEPTICUS TIMELINE:</strong><br>
    <br>
    <strong>0-5 MINUTES (STABILIZATION):</strong><br>
    ‚Ä¢ ABCDE, oxygen, IV access x2<br>
    ‚Ä¢ Check glucose, treat if <4 mmol/L<br>
    ‚Ä¢ Thiamine 100mg IV if at risk of deficiency<br>
    ‚Ä¢ Consider toxicology screen<br>
    <br>
    <strong>5-20 MINUTES (BENZODIAZEPINES):</strong><br>
    ‚Ä¢ Lorazepam 0.1 mg/kg IV (max 4mg) OR<br>
    ‚Ä¢ Midazolam 0.2 mg/kg IM (if no IV) OR<br>
    ‚Ä¢ Diazepam 0.15 mg/kg IV (max 10mg)<br>
    ‚Ä¢ Repeat once in 5-10 minutes if ongoing<br>
    <br>
    <strong>20-40 MINUTES (ANTIEPILEPTICS):</strong><br>
    ‚Ä¢ Fosphenytoin 20 mg PE/kg (max 150 mg PE/min) OR<br>
    ‚Ä¢ Valproate 40 mg/kg (max 6 mg/kg/min) OR<br>
    ‚Ä¢ Levetiracetam 60 mg/kg (max 4.5g over 15 min)<br>
    <br>
    <strong>>40 MINUTES (REFACTORY):</strong><br>
    ‚Ä¢ RSI: Propofol 1-2 mg/kg OR Thiopental 4-5 mg/kg<br>
    ‚Ä¢ Continuous EEG monitoring<br>
    ‚Ä¢ Midazolam infusion 0.1-0.4 mg/kg/hr OR<br>
    ‚Ä¢ Propofol infusion 1-15 mg/kg/hr (watch for propofol infusion syndrome)<br>
    ‚Ä¢ Consider ketamine 1-3 mg/kg load, then 0.5-10 mg/kg/hr
</div>

<h3>10.2 Raised ICP Management</h3>

<div class="icp-alert">
    <strong>üß† RAISED ICP >20 mmHg:</strong><br>
    1. Head elevation 30¬∞ (if spine cleared)<br>
    2. Normocapnia (PaCO‚ÇÇ 35-40 mmHg)<br>
    3. Mannitol 0.25-1 g/kg OR Hypertonic saline 3% 250 mL over 30 min<br>
    4. Sedation: Propofol 5-50 mcg/kg/min<br>
    5. Analgesia: Fentanyl 1-2 mcg/kg/hr<br>
    6. Neuromuscular blockade if agitated: Rocuronium 0.6-1.2 mg/kg<br>
    7. Barbiturate coma: Thiopental 5-10 mg/kg load, then 3-5 mg/kg/hr<br>
    8. Decompressive craniectomy (neurosurgical consult)
</div>

<h3>10.3 Acute Agitation Management (The "5 and 2" Protocol)</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th>Scenario</th>
            <th>First Choice</th>
            <th>Alternative</th>
            <th>Special Considerations</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Undifferentiated agitation</strong></td>
            <td>Haloperidol 5mg IM + Lorazepam 2mg IM</td>
            <td>Olanzapine 10mg IM (atypical antipsychotic)</td>
            <td>Check QT interval if high doses needed</td>
        </tr>
        <tr>
            <td><strong>Known psychiatric illness</strong></td>
            <td>Their usual antipsychotic + Benzodiazepine</td>
            <td>Risperidone 2mg PO/IM if atypical preferred</td>
            <td>Consider depot preparation if non-adherent</td>
        </tr>
        <tr>
            <td><strong>Delirium (hyperactive)</strong></td>
            <td>Haloperidol 0.5-2mg IV/IM</td>
            <td>Quetiapine 25-100mg PO</td>
            <td>Avoid benzodiazepines (may worsen confusion)</td>
        </tr>
        <tr>
            <td><strong>Substance intoxication</strong></td>
            <td>Benzodiazepine alone (Lorazepam 2mg IM)</td>
            <td>Observation, supportive care</td>
            <td>Avoid antipsychotics (lower seizure threshold)</td>
        </tr>
        <tr>
            <td><strong>Alcohol withdrawal</strong></td>
            <td>Lorazepam 2-4mg IV/IM (CIWA protocol)</td>
            <td>Diazepam 10mg IV/PO</td>
            <td>Symptom-triggered dosing reduces total dose</td>
        </tr>
    </tbody>
</table>

<!-- APPENDIX: QUICK REFERENCE GUIDES -->
<div class="page-break"></div>
<h2>Appendix: Quick Reference Guides</h2>

<h3>Status Epilepticus Drug Comparison</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th>Drug</th>
            <th>Dose</th>
            <th>Onset</th>
            <th>Duration</th>
            <th>Advantages</th>
            <th>Disadvantages</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Lorazepam</strong></td>
            <td>0.1 mg/kg IV</td>
            <td>2-5 min</td>
            <td>12-24h</td>
            <td>Long duration, evidence-based</td>
            <td>Respiratory depression</td>
        </tr>
        <tr>
            <td><strong>Midazolam IM</strong></td>
            <td>0.2 mg/kg IM</td>
            <td>5-15 min</td>
            <td>1-2h</td>
            <td>No IV needed, well absorbed</td>
            <td>Short duration</td>
        </tr>
        <tr>
            <td><strong>Diazepam</strong></td>
            <td>0.15 mg/kg IV</td>
            <td>2 min</td>
            <td>15-30 min</td>
            <td>Fastest brain entry</td>
            <td>Very short duration, active metabolites</td>
        </tr>
        <tr>
            <td><strong>Fosphenytoin</strong></td>
            <td>20 mg PE/kg</td>
            <td>10-30 min</td>
            <td>24h</td>
            <td>Water-soluble, IM option</td>
            <td>Cardiotoxic, enzyme inducer</td>
        </tr>
        <tr>
            <td><strong>Valproate</strong></td>
            <td>40 mg/kg</td>
            <td>10-15 min</td>
            <td>24h</td>
            <td>Broad spectrum, well tolerated</td>
            <td>Hepatotoxic, teratogenic</td>
        </tr>
        <tr>
            <td><strong>Levetiracetam</strong></td>
            <td>60 mg/kg</td>
            <td>15-30 min</td>
            <td>24h</td>
            <td>Few interactions, no monitoring</td>
            <td>Expensive, behavioral side effects</td>
        </tr>
    </tbody>
</table>

<h3>Opioid Overdose: Which Opioid, Which Antidote?</h3>

<div class="overdose-alert">
    <strong>üíâ OPIOID HALF-LIVES vs NALOXONE DURATION:</strong><br>
    ‚Ä¢ <strong>Heroin:</strong> 3-5 min (active metabolite morphine 3-4h) ‚Üí Observe 4-6 hours<br>
    ‚Ä¢ <strong>Morphine:</strong> 2-4 hours ‚Üí Observe 6-8 hours<br>
    ‚Ä¢ <strong>Oxycodone:</strong> 3-5 hours ‚Üí Observe 8-10 hours<br>
    ‚Ä¢ <strong>Methadone:</strong> 24-36 hours ‚Üí May need infusion for 24-48 hours<br>
    ‚Ä¢ <strong>Fentanyl:</strong> 2-4 hours (but patches 72h) ‚Üí Observe 4-6 hours (patches 24h+)<br>
    ‚Ä¢ <strong>Buprenorphine:</strong> 24-60 hours ‚Üí May need high-dose naloxone<br>
    <em>Naloxone duration: 30-90 minutes ‚Üí RE-DOSE OFTEN!</em>
</div>

<h3>Monitoring Parameters for Neuro-Psych Drugs</h3>
<ul>
    <li><strong>Benzodiazepines:</strong> Respiratory rate, SpO‚ÇÇ, level of consciousness</li>
    <li><strong>Phenytoin/fosphenytoin:</strong> ECG, BP during infusion; levels at 2h post-load</li>
    <li><strong>Phenobarbital:</strong> Respiratory rate, BP; levels at 2-4h post-load</li>
    <li><strong>Mannitol:</strong> Serum osmolality (target 300-320), electrolytes, urine output</li>
    <li><strong>Haloperidol:</strong> ECG (QT interval), extrapyramidal symptoms, temperature (NMS)</li>
    <li><strong>Naloxone:</strong> Respiratory rate, withdrawal signs, re-sedation</li>
    <li><strong>General:</strong> Neurological observations (GCS) every 15-30 minutes initially</li>
</ul>

<div class="study-format">
    <h2><span class="emoji">üß†</span> DRUG TEMPLATE SUMMARY FOR MODULE 4</h2>
    <p><strong>All 8 drugs in this module follow the consistent 11-point format:</strong></p>
    <ol>
        <li><strong>Drug class</strong> - Pharmacological category</li>
        <li><strong>Mechanism of action</strong> - How it works at receptor/physiological level</li>
        <li><strong>Indications</strong> - Specific neurological/psychiatric emergencies</li>
        <li><strong>Contraindications</strong> - Absolute and relative contraindications</li>
        <li><strong>Adult dose</strong> - Exact emergency dosing (bolus, infusion, max)</li>
        <li><strong>Pediatric dose</strong> - Weight-based calculations</li>
        <li><strong>Route & preparation</strong> - How to prepare and administer safely</li>
        <li><strong>Side effects</strong> - Common, expected effects</li>
        <li><strong>Adverse effects / ADR</strong> - Serious reactions and toxicity</li>
        <li><strong>Drug interactions</strong> - Important combinations to avoid/watch</li>
        <li><strong>Emergency pearls</strong> - Clinical tips, exam favorites, practical wisdom</li>
    </ol>
</div>

<div class="footer-note">
    <strong>¬© Emergency Medicine Education Team | Confidential Educational Material</strong><br>
    This document is for educational purposes only. Always follow local protocols and guidelines.<br>
    Medications and doses may vary by institution. Verify all information before clinical application.<br>
    Version 1.0 | Last updated: [Current Date] | Module 4 of 10
</div>
</body> </html>